Clinical Trial Update: Extended Niacin/Laropiprant in Patients With Type 2 Diabetes (0524A-069) [Phase 3]

View source ↗

Summary

This entry reports the completion of a Phase 3 trial evaluating extended niacin combined with laropiprant in patients with Type 2 diabetes mellitus, with result…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Laropiprant (laropiprant)
• Niacin (nicotinic acid)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Diabetes Mellitus Type 2 | Phase 3 | Status: COMPLETED | Results posted: 2009-09-11